MarketWatch reports that Encorium Group, Inc, which is a multi-national contract research organization, has announced the signing of $3.5 million of new business contracts with a global biopharmaceutical company.
This contract will cover clinical trials in the field of vaccines for infectious diseases in multiple European countries. Kenneth M. Borow, M.D., Encorium Group's President mentions:
"With the signing of these contracts, Encorium has announced approximately $13.5 million of new business during the past three weeks. In aggregate, these new contracts represent both repeat and new client business and cover a wide array of therapeutic areas for multiple small as well as large biopharmaceutical companies. Encorium will provide clinical trial services for these studies on three continents including North America, Europe, and
No comments:
Post a Comment